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Abstract  31 
 32 
Neuronal circuits in the hypothalamus and hindbrain are of importance for 33 
control of food intake, energy expenditure and fat mass. We have recently shown 34 
that treatment with exendin-4 (Ex-4), an analogue of the pro-glucagon derived 35 
molecule glucagon-like peptide 1 (GLP-1), markedly increases mRNA-expression 36 
of the cytokine interleukin-6 (IL-6) in the hypothalamus and hindbrain, and that 37 
this increase partly mediates the suppression of food intake and body weight by 38 
Ex-4. Endogenous GLP-1 in the central nervous system (CNS) is produced by 39 
preproglucagon (PPG) neurons of the nucleus of the solitary tract (NTS) in the 40 
hindbrain. These neurons project to various parts of the brain, including the 41 
hypothalamus. Outside the brain, IL-6 stimulates GLP-1 secretion from the gut and 42 
pancreas.  43 
In this study, we aim to investigate whether IL-6 can affect GLP-1 producing PPG 44 
neurons in the NTS in mouse hindbrain via the ligand binding part of the IL-6 45 
receptor, IL-6 Receptor-α (IL-6Rα).  46 
Using immunohistochemistry, we found that IL-6Rα was localized on PPG 47 
neurons of the NTS. Recordings of these neurons in GCaMP3/GLP-1 reporter 48 
mice showed that IL-6 enhances cytosolic Ca2+ concentration in neurons capable 49 
of expressing PPG. We also show that the Ca2+ increase originates from the 50 
extracellular space. Furthermore, we found that IL-6Rα was localized on cells in 51 
the caudal hindbrain expressing immunoreactive NeuN (a neuronal marker) or 52 
CNPase (an oligodendrocyte marker). 53 
In summary, IL-6Rα is present on PPG neurons in the NTS, and IL-6 can stimulate 54 
these cells by increasing influx of Ca2+ to the cytosol from the extracellular space. 55 
 56 
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 62 
Introduction 63 
 64 
It is well established that interleukin-6 (IL-6) contributes to stimulation of the 65 
innate immune system and induction of inflammation (1). In addition, IL-6 is 66 
important for the decreased appetite, enhanced energy metabolism and increased 67 
body temperature often observed during disease (6, 36). During inflammation 68 
and disease IL-6, along with other cytokines, acts via nervous afferents to induce a 69 
disease response in the brain (33). During more severe disease, circulating 70 
cytokines in the blood stream are thought to act on the circumventricular organs 71 
to induce a more pronounced disease response (9). 72 
 73 
In healthy mice, IL-6 acts in lower concentrations than those observed during 74 
disease to cause a tonic decrease in body fat mass and an increase in energy 75 
expenditure (24, 38, 39). We, as well as others, have shown that IL-6-/- mice 76 
develop mature onset obesity (24, 39). The anti-obesity effect of IL-6 in rodents is 77 
partly exerted at the level of the brain, presumably the hypothalamus and the 78 
hindbrain (22, 38, 39). Deficiency of IL-6 decreases leptin sensitivity, while 79 
overexpression of IL-6 in the brain enhances this parameter (12, 30, 39). Taken 80 
together, these findings suggest that IL-6 levels below those found in normal 81 
healthy individuals promote obesity (12, 24, 29, 39), while levels above normal 82 
may reduce appetite (7, 30). Therefore, it is important to identify which cells in 83 
the brain that express functional interleukin-6 receptor (IL-6Rα), and to 84 
determine whether these cells are localized in nuclei that regulate appetite and/or 85 
energy balance. Such a mapping of IL-6Rα has been done for body fat regulating 86 
centers in the hypothalamus (3, 31, 32, 40) while there are fewer studies on the 87 
hindbrain, another part of the brain regulating metabolic functions (14).  88 
 89 
The proglucagon system includes proglucagon derived post-translational cleavage 90 
products such as Glucagon-like peptide 1 (GLP-1) (2). GLP-1 is an incretin with 91 
important effects on both blood glucose levels and fat mass. Outside the central 92 
nervous system (CNS), GLP-1 is mainly synthesized in the entero-endocrine L-93 
cells in the distal gut and to some extent in the proximal gut (37). GLP-1 may also 94 
be produced by pancreatic α-cells (11). Within the CNS, GLP-1 is expressed in 95 
preproglucagon neurons in the nucleus of the solitary tract (NTS) in the 96 
brainstem. The anti-obesity effect of peripheral GLP-1 is assumed to be exerted 97 
via activation of vagal afferent fibres (10, 18). Whether these vagal afferents in 98 
turn activate the PPG neurons in the NTS to initiate central release of GLP-1 is 99 
currently under debate(17). Leptin and CCK are known to stimulate PPG neurons 100 
in the NTS, while several other appetite and/or peptides regulating body fat and 101 
food intake, including GLP-1 itself, have no effect (16, 17). These data are in line 102 
with the assumption that GLP-1 in NTS regulates body fat mass, and that this 103 
effect is exerted via interaction with other peptides regulating body fat and food 104 
intake such as leptin and CCK.  105 
 106 
In recent studies we reported that treatment with Exendin-4 (Ex4), a long-lasting 107 
GLP-1 analogue, enhances the expression of IL-6 in both the hypothalamus and 108 
different parts of the hindbrain. We provided evidence that increased IL-6 109 
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expression mediates the anti-obesity effect of GLP-1 (28, 34). Similarly, it has 110 
recently been shown that amylin, an anti-obesity and blood glucose regulating 111 
hormone, induces central IL-6 production which in turn leads to increased leptin 112 
sensitivity (21).  113 
 114 
As discussed above, GLP-1 inhibits fat mass in part by stimulating IL-6 expression 115 
(34). To further investigate possible interactions between GLP-1 and IL-6, we 116 
sought to determine whether PPG neurons express functional IL-6Rα. Because 117 
GLP-1 in the CNS is almost exclusively produced in the NTS, we stained for IL-6Rα 118 
in brain slices from this area. Furthermore, we performed optical recordings 119 
using Glu-Cre/Rosa26GCaMP3 transgenic mice to investigate whether IL-6 can 120 
affect these neurons by modulation of Ca2+ influx and cytosolic Ca2+ 121 
concentrations.  122 
 123 
We have previously found that IL-6Rα is expressed in several different types of 124 
neurons in hypothalamic nuclei (3, 31, 32). Besides neurons, the parenchymal 125 
brain also consists of three different types of glial cells; astrocytes, microglia and 126 
oligodendrocytes. In the present study we aimed to systematically elucidate 127 
whether IL-6Rα in the NTS is expressed on neurons and/or different types of glial 128 
cells.  129 
Methods 130 
 131 
Animals  132 
  133 
Two transgenic C57BL6 mouse models were used in this study. Firstly, PPG 134 
neurons were visualized using glucagon promoter (Glu)-YFP mice, in which 135 
yellow fluorescent protein (YFP) is expressed under the control of the glucagon 136 
promoter (23, 27). These mice were used for double staining of YFP and immuno-137 
reactive IL-6Rα. GCaMP3 mice were used for immuohistochemical validation of 138 
the model. Standard wild type C57BL6 mice were used for the rest of the 139 
immunohistochemistry. Glu-Cre/Rosa26-GCaMP3 transgenic mice expressing the 140 
genetically encoded calcium indicator GCaMP3 in a Cre-dependent manner were 141 
obtained by crossing Glu-Cre mice (26) with commercially available Rosa26-142 
GCaMP3 reporter mice (Jax strain 014538) (41) resulting in expression of the 143 
genetically encoded Ca2+-sensor GCAMP3 in PPG neurons (Fig. 1A).  144 
 145 
Animals had free access to water and standard chow pellets (Tekland Global, 146 
Harlan, The Netherlands), and were kept under standardized conditions on 12 h 147 
light/dark cycle with ad libitum food. The local ethics committees for animal care 148 
at the University of Gothenburg and University College London (UCL) approved all 149 
animal procedures, respectively, and studies at UCL were conducted in accordance 150 
with the U.K. Animals (Scientific Procedures) Act, 1986. 151 
 152 
Tissue preparation for immunohistochemistry  153 
 154 
Mice were deeply anaesthetized and perfused transcardially with heparinized 155 
saline (50 IU/ml) followed by 4% paraformaldehyde in 0.1M phosphate buffer. 156 
The brains were removed and post fixed in 4% paraformaldehyde in 0.1M 157 
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phosphate buffer containing 15% sucrose overnight at 4 °C. They were then 158 
transferred to a 30% sucrose solution in 0.1M phosphate buffer until sectioning. 159 
Coronal 20μm thick serial sections of the hypothalamus and hindbrain were cut 160 
using a Leica CM3050S cryostat (Leica Microsystem, Wetzlar, Germany) and 161 
stored in cryoprotectant solution (25% ethylene glycol; 25% glycerol; 0.05 m 162 
phosphate buffer). For GFP/GLP-1 co-staining, we instead used 30 um sections 163 
that were not post fixed in 4% paraformaldehyde in 0.1M phosphate buffer 164 
containing 15% sucrose overnight. Coronal sections corresponding to bregma -165 
7,32 to -7,64 (interneural -3,52 to -3,84) were selected for staining.  166 
 167 
Immunohistochemistry 168 
 169 
Briefly, sections were rinsed in wash buffer (0.1M TrisHCl, pH 7.5, 0,15M NaCl, 170 
0.2% Triton-X-100) and blocked for 1 h with TNB (Perkin Elmer, Waltham, MA, 171 
USA). Sections were incubated with primary antibodies (see supplementary table) 172 
for 2 days at 4 °C. After rinsing, sections were incubated for 1 h with secondary 173 
antibodies (see supplementary table) diluted in TNB blocking reagent. Sections 174 
were rinsed, and the IL-6Rα signal was developed by incubating the sections in 175 
Streptavidin-horseradish peroxidase in TNB blocking reagent (1:100, TSA™ 176 
System; Perkin Elmer) for 30 min and then with biotinyl-tyramide in amplification 177 
diluent (1:50, TSA™ System; Perkin Elmer). Following signal amplification, 178 
sections were stained with Streptavidin Alexa fluor 568-conjugate (1:250, S11226; 179 
Molecular Probes, Carlsbad, CA, USA). After a further wash, cell nuclei were stained 180 
with DAPI (1:5000, D1306; Molecular Probes) for 15 min, rinsed and mounted in 181 
mounting medium containing prolong gold antifade (P36930; Molecular Probes). 182 
As a control for the secondary antibodies, some sections were incubated with 183 
mismatching primary and secondary antibodies, resulting in negative staining (as 184 
a control for unwanted cross-reactivity). The rat anti-IL-6α antibody used in the 185 
present studied has been validated in several earlier studies (31, 32). Primary 186 
antibodies, their dilutions and catalogue numbers, as well as the manufacturers 187 
providing them are listed in Table 1. 188 
 189 
Confocal microscopy and cell counting 190 
 191 
Images of the stained sections were obtained using either a confocal microscope 192 
system (LSM 700; ZEISS, Oberkochen, Germany), together with a Plan APO ×63 193 
A/1.40 oil lens (for close-up pictures) or a Plan Fluor ×20/0.75 lens (for 194 
anatomical overview pictures) and a solid-state laser. For co-localization between 195 
IL-6rα and GLP-1, focus stacking was used to achieve a greater depth of field and 196 
as such make it possible to more accurately detect possible co-localization. 197 
NTS YFP-labeled cells and IL6-rα-positive cells were quantified from at least 4 20 198 
um sections per brain. Triple channel confocal images (to cover the entire NTS) 199 
were generated with a Plan Fluor ×20/0.75 lens and a solid-state laser. A tile scan 200 
of 3x3 tiles was obtained from the center of the NTS, covering the entirety of the 201 
nucleus. Neurons were considered IL-6Rα-labeled when the staining was clearly 202 
above background. The emission spectrum of the secondary fluorescent antibody 203 
is well known. By adjusting the splits of the confocal microscope, the signal of the 204 
6 
fluorophore was maximized while minimizing background fluorescence. The 205 
evaluation of IL-6Rα-labeling was done with the cell nucleus in the plane of focus. 206 
 207 
Calcium imaging 208 
 209 
Glu-Cre/Rosa26-GCaMP3 transgenic mice express the calcium indicator GCaMP3 210 
in PPG neurons selectively. To confirm that GCaMP3 positive cells in the NTS 211 
produce GLP-1, double immunofluorescence was carried out with an anti-GFP 212 
antibody (Abcam) to detect GCaMP3 (25), and an anti-GLP-1 antibody (Bachem) 213 
to detect GLP-1 (15). As shown in Fig 1 B-D, the anti-GLP-1 antibody detected 214 
essentially all GCaMP3/GFP positive cells, but also cells that were not 215 
GCaMP3/GFP positive. This could indicate that visualization of GCaMP3/GFP 216 
expressing cells has incomplete penetrance, e.g due to lack of IL-Ra in about 60% 217 
of GLP-1 expressing cells (Fig 2G). Alternatively, the GLP-1 antibody may bind 218 
nonspecifically to additional cells that do not have GLP-1 and GCaMP3 expression 219 
and thereby are not stained. All cells expressing GCaMP3 were positive for GLP-1.  220 
On the day of recording mice underwent deep terminal anaesthesia using 221 
isofluorane. The brainstem was removed and placed in ice-cold high-222 
magnesium/low-calcium artificial cerebrospinal fluid (ACSF) (composition in mM: 223 
2.5 KCl, 200 sucrose, 28 NaHCO3, 1.25 NaH2PO4, 7 Glucose, 7 MgCl2, 0.5 CaCl2; pH 224 
7.4). 200μm thick coronal sections were cut on a vibratome (Campden 225 
Instruments) and left to incubate in high-magnesium/low-calcium recovery 226 
solution (in mM: 3 KCl, 118 NaCl, 25 NaHCO3, 1.2 NaH2PO4, 2.5 Glucose, 7 MgCl2, 227 
0.5 CaCl2; pH 7.4) at 34⁰C for 45 minutes. Subsequently, the sections were 228 
transferred to standard ACSF (in mM: 3 KCl, 118 NaCl, 25 NaHCO3, 10 Glucose, 1 229 
MgCl2, 2 CaCl2; pH7.4) and left to incubate at 34⁰C for a minimum of 30mins 230 
before imaging. All solutions were constantly bubbled with 95% O2/5% CO2. 231 
Imaging was performed on a Zeiss Axioskop widefield microscope using a 40x 232 
water immersion lens, CCD camera (Q-click; QImaging) and a LED light source 233 
(CoolLED pE300white). Sections were continuously superfused with standard ACSF 234 
at 32⁰C at a flow rate of 3-4ml/min. GCaMP3 was excited every 5 seconds for 235 
250ms at 460nm+/-25nm. Regions of interest (ROIs) and an area representing 236 
background fluorescence were outlined and the mean pixel intensity calculated 237 
for each ROI. Background fluorescence was subtracted from each ROI and 238 
recordings are presented as ΔF/F0 with F0 being the average intensity over 5 239 
minutes prior to the stimulus and ΔF being the fluorescence intensity minus F0.  240 
Quantifications were made by calculating the relative change in fluorescence 241 
between the fluorescent intensity in the absence of drug (Fno-drug) and the peak 242 
fluorescent intensity (Fpeak): (Fpeak-Fno-drug)/Fno-drug. Fno-drug was defined as the 243 
average of 1 minute before drug response onset and 1 minute after recovery from 244 
the response. IL-6 was dissolved in water and added directly to the ACSF. For 245 
recordings in the nominal absence of Ca2+, Ca2+ was replaced with Mg2+. All 246 
sections were exposed to 2nM IL-6, followed by a second exposure to IL-6 in 0mM 247 
Ca2+, and finally exposed again to 2nM IL-6 in standard ACSF. Data are reported as 248 
mean±SEM. Statistics were analyzed using one-way ANOVA and post-hoc 249 
comparisons were made using the Bonferroni method. 250 
 251 
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Results 253 
7 
 254 
IL-6Rα immunoreactivity is present in the NTS and is co-localized with GLP-255 
1. 256 
 257 
Immunofluorescence staining of hindbrain sections from Glu-YFP mice revealed 258 
YFP-positive neurons activated by the Glu promoter (in green) co-localized with 259 
IL-6Rα immunoreactivity (in red)(Fig 2A-D). Three examples of cells expressing 260 
both IL-6 Rα and YFP, are shown in Fig 2B and Fig 2D (orange arrows). 261 
Orthogonal images made from z-stacks focused on single cells clearly identified 262 
two cells with both IL-6 Rα and GLP-1 as shown in in Fig 2B and 2D. Orthogonal 263 
images made from z-stacks, focused on single cells with only IL-6Rα (white arrow) 264 
or only GLP-1 (green arrow), are shown in in Fig 2E and 2F, respectively. Cell 265 
counting showed that 38,5 % of the GLP-1 positive cells of the NTS also stained 266 
positively for IL-6Rα. Conversely, 13% of the IL-6Rα positive cells of the NTS also 267 
stained positively for GLP-1 (Fig 2G). Use of separate filters on the same area of 268 
the NTS, as seen in Fig 2D, verified the co-localization results described above (not 269 
shown).  270 
 271 
PPG neurons in the NTS respond to IL-6 with an increase in intracellular 272 
Ca2+  273 
 274 
In vitro calcium imaging was performed using adult Glu-Cre/Rosa26-GCaMP3 275 
mice to characterize the functional response of PPG neurons to IL-6 (Fig. 3). 276 
Bath-application of 2nM IL-6 led to an 8%±1.5% increase in intracellular Ca2+ in 277 
PPG neurons (Fig 3B). To determine the source of the increase in intracellular Ca2+ 278 
experiments we repeated the exposures to IL-6, but in the absence of extracellular 279 
Ca2+. Removal of extracellular calcium strongly reduced the intracellular Ca2+ (Fig 280 
3C; top panel) an effect that was reversed upon reintroduction of extracellular 281 
Ca2+. The fact that the effect of IL-6 was reduced by about 90 % in the absence of 282 
extracellular Ca2+ suggests that Ca2+ influx is necessary for the response to IL-6 283 
(Fig. 3C; bottom panel). 284 
 285 
IL-6Rα immunoreactivity in the NTS is present on neurons and 286 
oligodendrocytes, but not on astrocytes or microglia. 287 
 288 
In the hindbrain, immunofluorescent co-staining revealed that IL-6Rα 289 
immunoreactivity (in green) in many cells was co-localized with a marker for 290 
neuronal nuclei (NeuN, in red) (Fig 4A-B; orange arrows). There were numerous 291 
NeuN positive cells without IL-6Rα (Fig 4B, red arrows show examples). 292 
Additionally, IL-6Rα immunoreactivity (in green) co-localized in many cells with a 293 
marker for oligodendrocytes (CNP:ase, in red). (Fig 4C-D; orange arrows show 294 
examples). There were IL-6Rα positive cells without CNP:ase (white arrows show 295 
examples). In contrast, IL-6Rα immunoreactivity was not co-expressed with 296 
markers for microglia (Iba-1; Fig 5A-B) or astrocytes (GFAP; Fig 5C-D). The co-297 
localization between IL-6Rα and the four cellular markers was verified in a focus 298 
stacking projection (Fig panels 4B, 4D, 5B, 5D). 299 
Cell counting showed that 30 % of the cells expressing NeuN and CNP:ase were 300 
also IL-6Ra positive. Conversely, 60% and 30% of the IL-6Rα positive cells, were 301 
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also positive for NeuN and CNP:ase, respectively. There was no co-localization 302 
between GFAP and Iba-1 on one hand and IL-6Rα on the other (Table 2). 303 
 304 
Discussion 305 
 306 
It has previously been shown that IL-6 in CNS is of importance in regulation of 307 
energy metabolism, and that IL-6 acts at the CNS level to decrease fat mass (20, 308 
31, 34). IL-6-/- mice develop mature onset obesity as well as insulin and leptin 309 
resistance (24, 38). GLP-1 analogues, like Exendin-4 (Ex4), have also been shown 310 
to decrease fat mass by acting at the CNS level (15). Ex4 is widely used as a 311 
treatment for type 2 diabetes, where the beneficial side effects include mild weight 312 
loss (10). Recently liraglutide, another GLP-1 analogue, has been used for 313 
treatment of obesity per se (19). We have previously shown that 314 
intracerebroventricular injections of Ex4 increases IL-6 mRNA levels both in 315 
several parts of the hindbrain and in the hypothalamus, and that IL-6 is mediating 316 
the anti-obesity effect exerted by this GLP-1 analogue (28, 34). These findings led 317 
us to further study the possible interactions between these two neuromodulators, 318 
to elucidate how they may interact to decrease fat mass.  319 
 320 
Our present finding that IL-6Rα is expressed in PPG neurons in the NTS of the 321 
hindbrain indicates that IL-6 has the capacity to influence GLP-1 expressing 322 
neurons in the CNS via direct effects on IL-6Rα located on these neurons, in a 323 
similar way as shown for leptin (16). As noted above, treatment with a GLP-1 324 
analog increases the levels of IL-6 mRNA in the hypothalamus and the hindbrain 325 
(34). Taken together, these findings are in line with a bidirectional interaction 326 
between PPG neurons and IL-6 neurons. Such interactions are common in 327 
biological context, and there are both general (4) and specific (13) examples of 328 
this. However, further studies are needed to investigate if there is a bidirectional 329 
interaction between GLP-1 and IL-6 producing cells, and if so, the nature of this 330 
interaction.  331 
Whilst results obtained by immunohistochemistry should always be interpreted 332 
with caution, there is good reason to believe the co-localization between GLP-1 333 
and IL-6Rα observed herein is valid. Firstly, we have previously identified IL-6Rα 334 
by use of two independent antibodies (31, 32). Secondly, the Glu-YFP transgenic 335 
mouse used here has been thoroughly validated (16, 23, 27, 28). Thirdly, the co-336 
staining was verified using focal stacking as well as three-dimensional analysis 337 
seen in Fig 2B and D-F. Finally, the fact that PPG/GLP-1 expressing cells (identified 338 
by both glucagon promoter activity and GLP-1 immunoreactivity) in the NTS 339 
responded to addition of IL-6 strongly support that these cells express functional 340 
IL-6Rα. Taken together, these methods make it reasonable to believe that the co-341 
staining shown is reliable. 342 
GCaMP3 recordings revealed that adding IL-6 to mouse acute hindbrain sections 343 
resulted in an influx of Ca2+ in PPG neurons, similarly to what has previously been 344 
shown in hippocampal neurons (25).  Our finding that IL-6 seems to stimulate 345 
PPG neurons adds further information concerning the interaction between these 346 
substances.  We have previously shown that i.c.v injections of Ex4 in rat causes an 347 
increase in IL-6 mRNA (34) and we show here that IL-6 in turn can stimulate PPG 348 
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neurons. One possible interpretation is that a GLP-1 analogue like Ex4 can 349 
stimulate endogenous GLP-1 secretion, acting on NTS PPG neurons via IL-6. It has 350 
been shown that GLP-1 itself cannot activate these PPG neurons (16). This would 351 
constitute a feed forward effect, a type of effect seen for instance in connection to 352 
immune stimulation. Further studies are needed to investigate this issue.  353 
It should be noted that IL-6 outside the brain has been found by Donath and 354 
coworkers to stimulate the secretion of GLP-1 from L-cells of the gut and α-cells of 355 
the pancreas (11). Our current data suggest that IL-6 also stimulates a third GLP-1 356 
expressing cell type, the PPG neurons in the NTS. It is currently unclear whether 357 
circulating IL-6 or IL-6 produced locally in the brain influences PPG neurons in the 358 
NTS. Circulating IL-6 may not cross the blood brain barrier, and therefore not 359 
reach the NTS. Unlike e.g the area postrema, the NTS is not a circumventricular 360 
organ and thus cannot be affected directly by peripherally produced peptides like 361 
IL-6 (5). The fact that IL-6 levels in the cerebrospinal fluid often are higher than in 362 
the blood circulation, also argues that IL-6 found in the brain is produced locally 363 
rather than in the periphery (35).  364 
  365 
We have previously reported that IL-6Rα is expressed in important energy-366 
regulatory neurons in the paraventricular nucleus (PVN) (3), in the arcuate 367 
nucleus (ARC) (31) and in the lateral hypothalamic area (LHA) of the 368 
hypothalamus (32). Neurons expressing IL-6Rα have been reported to express 369 
several neuropeptides with energy balance regulating potential, such as TRH, CRH, 370 
oxytocin, MCH, orexin, NPY and a-MSH (3, 31, 32). Here we show that IL-6Rα is 371 
expressed in parts of the brainstem as well as in the hypothalamus.  372 
 373 
There was no obvious co-localization between IL-6Rα and markers for astrocytes 374 
and microglia, although it cannot be completely ruled out that IL-6Rα and the 375 
markers are localized in different compartments within the same cell. In contrast, 376 
we found CNPase immunoreactivity in about 30 % of the IL-6Rα positive cells of 377 
the NTS. Therefore, IL-6Rα seems to be present on oligodendrocytes in this 378 
nucleus. This is in accordance with previous findings that IL-Rα can be found on 379 
oligodendrocytes in humans with multiple sclerosis as well as healthy controls (8). 380 
Moreover, we found that a large part (about 60%) of the cells that expressed IL-381 
6Rα in the NTS also expressed the neuronal marker NeuN. These findings from 382 
the caudal hindbrain are in line with results obtained from different parts of the 383 
hypothalamus (3, 31, 32). Taken together, these results indicate that IL-6 exerts its 384 
effects in caudal parts of the hindbrain and in the hypothalamus of healthy mice 385 
primarily on neurons and oligodendrocytes. 386 
 387 
In conclusion, our present findings show stimulation by IL-6 of PPG neurons and 388 
localization of IL-6Rα on these cells. In the caudal hindbrain of healthy mice, IL-389 
6Rα is expressed on neurons and oligodendrocytes, while we found no evidence of 390 
expression on astrocytes and microglia.  391 
 392 
 393 
Perspectives and Significance 394 
 395 
10 
In a previous study we found evidence that GLP-1 stimulates IL-6 expression in 396 
the CNS, and that IL-6 may mediate the anti-obesity effects of GLP-1 The present 397 
findings demonstrate that IL-6 in turn activates PPG neurons in the NTS. Given 398 
that GLP-1 stimulates IL-6 expression, there is a possibility for bidirectional 399 
interaction between cells producing GLP-1 and IL-6 In the CNS. Alternatively, IL-6 400 
produced in the periphery, may affect GLP-1 producing neurons in the CNS, as it 401 
has been shown to activate L-cells in the gut and alpha cells in the pancreas. The 402 
present findings are of clinical interest given that both GLP-1 analogues and IL-6 403 
receptor blockers are used for treatment in humans.  404 
 405 
Acknowledgements 406 
 407 
We thank the Centre for Cellular Imaging at the University of Gothenburg for the 408 
use of imaging equipment, as well as support received from Julia Fernandez-409 
Rodriguez, Maria Smedh and Carolina Tängemo. We also thank Edwin Gidestrand 410 
for assistance with immunohistochemistry. 411 
 412 
This work was supported by grants from Swedish Research Council (K2016–413 
54X-09894–19-3, 2011-3054 and 325–2008-7534), Johan och Jakob Söderbergs 414 
Foundation, Marcus Borgströms Foundation, Nilsson-Ehle Foundation, 415 
NovoNordisk Foundation, Novo Nordisk Foundation Excellence project grant (to 416 
KPS), Inga-Britt och Arne Lundbergs Foundation, Swedish Medical Society, 417 
Swedish Society for Medical Research, Kungl och Hvitfeldtska Foundation, EC 418 
FP7 funding (Health-F2–2010–259772, FP7/2007–2013 Grant Agreement 419 
245009, Full4Health FP7-KBBE-2010–4- 266408, TORNADO [grant 222720]). 420 
MK Holt holds a UCL Graduate Research Fellowship and S Trapp is supported by 421 
a grant from the MRC UK (MR/J013293/2) 422 
 423 
 424 
References 425 
 426 
1. Arora S, and Anubhuti. Role of neuropeptides in appetite regulation and 427 
obesity--a review. Neuropeptides 40: 375-401, 2006. 428 
2. Baggio LL, and Drucker, DJ. Biology of incretins: GLP-1 and GIP. 429 
Gastroenterology 132: 2131-2125, 2007. 430 
3. Benrick A, Schéle, E, Pinnock, SB, Wernstedt-Asterholm, I, Dickson, SL, 431 
Karlsson-Lindahl, L, and Jansson, JO. Interleukin-6 gene knockout 432 
influences energy balance regulating peptides in the hypothalamic paraventricular 433 
and supraoptic nuclei. Journal of Neuroendocrinology 21: 620-628, 2009. 434 
4. Blalock JE. A Molecular Basis for Bidirectional Communication Between 435 
the Immune and Neuroendocrine Systems. Physiological Reviews 69: 1989. 436 
5. Borison HL. Area postrema: Chemoreceptor circumventricular organ of 437 
the medulla oblongata. Progress in Neurobiology 32: 351-390, 1989. 438 
6. Cahlin C, Körner, A, Axelsson, H, Wang, W, Lundholm, K, and Svanberg, 439 
E. Experimental cancer cachexia: the role of host-derived cytokines interleukin 440 
(IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in 441 
11 
gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-442 
dependent cachexia. Cancer Research 60: 5488-5493, 2000. 443 
7. Campbell IL, Erta, M, Lim, SL, Frausto, R, May, U, Rose-John, S, Scheller, 444 
J, and Hidalgo, J. Trans-signaling is a dominant mechanism for the pathogenic 445 
actions of interleukin-6 in the brain. J Neurosci 34: 2503-2513, 2014. 446 
8. Cannella B, and Raine, CS. Multiple sclerosis: Cytokine receptors on 447 
oligodendrocytes predict innate regulation. Annals of Neurology 55: 46–57, 2004. 448 
9. Cartmell T, Poole, S, Turnbull, AV, Rothwell, NJ, and Luheshi, GN. 449 
Circulating interleukin-6 mediates the febrile response to localised inflammation 450 
in rats. The Journal of Physiology 526: 653-661, 2000. 451 
10. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 452 
117: 24–32, 2007. 453 
11. Ellingsgaard H, Hauselmann, I, Schuler, B, Habib, AM, Baggio, LL, 454 
Meier, DT, Eppler, E, Bouzakri, K, Wueest, S, Muller, YD, Hansen, AM, 455 
Reinecke, M, Konrad, D, Gassmann, M, Reimann, F, Halban, PA, Gromada, J, 456 
Drucker, DJ, Gribble, FM, Ehses, JA, and Donath, MY. Interleukin-6 enhances 457 
insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and 458 
alpha cells. Nature Medicine 17: 1481-1489, 2011. 459 
12. Flores MB, Fernandes, MF, Ropelle, ER, Faria, MC, Ueno, M, Velloso, LA, 460 
Saad, MJ, and Carvalheira, JB. Exercise improves insulin and leptin sensitivity in 461 
hypothalamus of Wistar rats. Diabetes 55: 2554-2561, 2006. 462 
13. Friedman JM, and Halaas, JL. Leptin and the regulation of body weight in 463 
mammals. Nature Medicine 395: 763–770, 1998. 464 
14. Grill HJ, and Hayes, MR. Hindbrain neurons as an essential hub in the 465 
neuroanatomically distributed control of energy balance. Cell Metabolism 16: 296-466 
309, 2012. 467 
15. Hayes MR, Leichner, TM, Zhao, S, Lee, GS, Chowansky, A, Zimmer, D, 468 
De Jonghe, BC, Kanoski, SE, Grill, HJ, and Bence, KK. Intracellular signals 469 
mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 470 
receptor activation. Cell Metab 2: 320-330, 2011. 471 
16. Hisadome K, Reimann, F , Gribble, FM, and Trapp, S. Leptin directly 472 
depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical 473 
properties of glucagon-like Peptide 1 neurons. Diabetes 59: 1890-1898, 2010. 474 
17. Hisadome K, Reimann, F, Gribble, FM, and Trapp, S. CCK Stimulation of 475 
GLP-1 Neurons Involves α1-Adrenoceptor–Mediated Increase in Glutamatergic 476 
Synaptic Inputs Diabetes 60: 2701-2709, 2011. 477 
18. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev 87: 1409 –478 
1439, 2007. 479 
19. Iepsen EW, Torekov, SS, and Holst, JJ. Therapies for inter-relating 480 
diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 15: 2487-481 
2500, 2014. 482 
20. Jansson JO, Wallenius, K, Wernstedt, I, Ohlsson, C, Dickson, SL, and 483 
Wallenius, V. On the site and mechanism of action of the anti-obesity effects of 484 
interleukin-6. Growth Horm IGF Res 13: S28-32, 2003. 485 
21. LeFoll C, Johnson, MD, Dunn-Meynell, AA, Boyle, CN, Lutz, TA, and 486 
Levin, BE. Amylin-induced central IL-6 production enhances ventromedial 487 
hypothalamic leptin signaling. Diabetes 64: 1621-1631, 2015. 488 
22. Li G, Klein, RL, Matheny, M, King, MA, Meyer, EM, and Scarpace, PJ. 489 
Induction of uncoupling protein 1 by central interleukin-6 gene delivery is 490 
12 
dependent on sympathetic innervation of brown adipose tissue and underlies one 491 
mechanism of body weight reduction in rats. Neuroscience 115: 879-889, 2002. 492 
23. Llewellyn-Smith IJ, Reimann, F, Gribble, FM, and Trapp, S. 493 
Preproglucagon neurons project widely to autonomic control areas in the mouse 494 
brain. Neuroscience 28: 111-121, 2011. 495 
24. Matthews VB, Allen, TL, Risis, S, Chan, MH, Henstridge, DC, Watson, N, 496 
Zaffino, LA, Babb, JR, Boon, J, Meikle, PJ, Jowett, JB, Watt, MJ, Jansson, JO, 497 
Bruce, CR, and Febbraio, MA. Interleukin-6-deficient mice develop hepatic 498 
inflammation and systemic insulin resistance. Diabetologia 53: 2431-2441, 2010. 499 
25. Orellana DI, Quintanilla, RA, Gonzalez-Billault, C, and Maccioni, RB. 500 
Role of the JAKs/STATs pathway in the intracellular calcium changes induced by 501 
interleukin-6 in hippocampal neurons. Neurotox Res 8: 295-304, 2005. 502 
26. Parker HE, Adriaenssens, A, Rogers, G, Richards, P, Koepsell, H, 503 
Reimann, F, and Gribble, FM. Predominant role of active versus facilitative 504 
glucose transport for glucagon-like peptide-1 secretion. . Diabetologia 55: 2445–505 
2455, 2012. 506 
27. Reimann F, Habib, AM, Tolhurst, G, Parker, HE, Rogers, GJ, and Gribble, 507 
FM. Glucose sensing in L cells: a primary cell study. Cell Metabolism 8: 532-539, 508 
2008. 509 
28. Richard JE, Farkas, I , Anesten, F, Anderberg, RH, Dickson, SL, Gribble, 510 
FM, Reimann, F, Jansson, JO, Liposits, Z, and Skibicka, KP. GLP-1 receptor 511 
stimulation of the lateral parabrachial nucleus reduces food intake: 512 
neuroanatomical, electrophysiological, and behavioral evidence. Endocrinology 513 
155: 4356-4367, 2014. 514 
29. Ruderman NB, Keller, C, Richard, AM, Saha, AK, Luo, Z, Xiang, X, Giralt, 515 
M, Ritov, VB, Menshikova, EV, Kelley, DE, Hidalgo, J, Klarlund Pedersen, B, and 516 
Kelly, M. Interleukin-6 regulation of AMP-activated protein kinase. Potential role 517 
in the systemic response to exercise and prevention of the metabolic syndrome. 518 
Diabetes 55: S48-52, 2006. 519 
30. Sadagurski M, Norquay, L, Farhang, J, D’Aquino, K, Copps, K, and 520 
White, MF. Human IL6 enhances leptin action in mice. Diabetologia 53: 525–535, 521 
2010. 522 
31. Schéle E, Benrick, A, Grahnemo, L, Egecioglu, E, Anesten, F, Pálsdóttir, 523 
V, and Jansson, JO. Inter-relation between interleukin (IL)-1, IL-6 and body fat 524 
regulating circuits of the hypothalamic arcuate nucleus. Journal of 525 
Neuroendocrinology 25: 580-589, 2013. 526 
32. Schéle E, Fekete, C, Egri, P, Füzesi, T, Palkovits, M, Keller, É, Liposits, Z, 527 
Gereben, B, Karlsson-Lindahl, L, Shao, R, and Jansson, JO. Interleukin-6 528 
receptor α is co-localised with melanin-concentrating hormone in human and 529 
mouse hypothalamus. J Neuroendocrinol 24: 930-943, 2012. 530 
33. Schettini G, Grimaldi, M, Landolfi, E, Meucci, O, Ventra, C, Florio, T, 531 
Scorziello, A, and Marino, A. Role of interleukin-6 in the neuroendocrine system. 532 
Acta Neurol (Napoli) 13: 361-367, 1991. 533 
34. Shirazi R, Palsdottir, V, Collander, J, Anesten, F, Vogel, H, Langlet, F, 534 
Jaschke, A, Schürmann, A, Prévot, V, Shao, R, Jansson, JO, and Skibicka, KP. 535 
Glucagon-like peptide 1 receptor induced suppression of food intake and body 536 
weight is mediated by central IL-1 and IL-6. ProcNatlAcadSci 110: 16199-16204, 537 
2013. 538 
13 
35. Stenlöf K, Wernstedt, I, Fjällman, T, Wallenius, V, Wallenius, K, and 539 
Jansson, JO. Interleukin-6 Levels in the Central Nervous System Are Negatively 540 
Correlated with Fat Mass in Overweight/Obese Subjects. JCEM 88: 4379 – 4383, 541 
2003. 542 
36. Strassmann G, Fong, M, Kenney, JS, and Jacob, CO. Evidence for the 543 
involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 544 
1681-1684, 1992. 545 
37. Svendsen B, Pedersen, J, Albrechtsen, NJ, Hartmann, B, Toräng, S, 546 
Rehfeld, JF, Poulsen, SS, and Holst, JJ. An analysis of cosecretion and 547 
coexpression of gut hormones from male rat proximal and distal small intestine. 548 
Endocrinology 156: 847-857, 2015. 549 
38. Wallenius K, Wallenius, V, Sunter, D, Dickson, SL, and Jansson, JO. 550 
Intracerebroventricular interleukin-6 treatment decreases body fat in rats. 551 
Biochem Biophys Res Commun 293: 560-565, 2002. 552 
39. Wallenius V, Wallenius, K, Ahrén, B, Rudling, M, Carlsten, H, Dickson, 553 
SL, Ohlsson, C, and Jansson, JO. Interleukin-6-deficient mice develop mature-554 
onset obesity. Nature Medicine 8: 75-79, 2002. 555 
40. Vallières L, and Rivest, S. Interleukin-6 is a needed proinflammatory 556 
cytokine in the prolonged neural activity and transcriptional activation of 557 
corticotropin-releasing factor during endotoxemia. Endocrinology 140: 3890-3903, 558 
1999. 559 
41. Zariwala HA, Borghuis, BG, Hoogland, TM, Madisen, L, Tian, L, De 560 
Zeeuw, CI, Zeng, H, Looger, LL, Svoboda, K, and Chen, TW. A Cre-dependent 561 
GCaMP3 reporter mouse for neuronal imaging in vivo. J Neurosci 32: 3131–3141, 562 
2012. 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
Figure Legends 583 
 584 
Table 1. Basic information about the primary and secondary antibodies used in 585 
this study.  586 
Antibody Dilution Cat. No Manufacturer
14 
Rat anti-IL-6Rα 1:20 BAM18301 R&D Systems, Minneapolis, MN, 
USA 
Rabbit anti-
GFAP 
1:200 Z 0334 DakoCytomation, Glostrup, 
Denmark 
Rabbit anti-
Iba1 
1:200 019-19741 Wako Chemicals, Richmond, VA, 
USA 
Mouse anti-
CNP:ase 
1:100 MAB326 Millipore, Billerica, MA, USA 
Rabbit anti-
NeuN 
1:100 ABN78 Millipore, Billerica, MA, USA 
Rabbit anti-
GLP-1 (7-36) 
amide 
1:200 T-4057 Peninsula Laboratories / 
Bachem, Torrance, CA, USA 
Goat anti-rat 
biotin 
1:1000 ab7096 abcam, Cambridge, UK 
Donkey Alexa 
fluor 488-
conjugated 
anti-rabbit IgG 
1:250 A21206 Molecular Probes, Carlsbad, CA, 
USA 
Rabbit Alexa 
fluor 488-
conjugated 
anti-mouse IgG 
1:250 A11059 Molecular Probes, Carlsbad, CA, 
USA 
Donkey Alexa 
fluor 568-
conjugated 
anti-rabbit IgG 
1:250 A10042 Molecular Probes, Carlsbad, CA, 
USA 
Donkey Alexa 
flour 568-
conjugated 
anti-mouse IgG 
1:250 A10037 Molecular Probes, Carlsbad, CA, 
USA 
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Table 2. Overlap between IL-6Rα positive cells and neuronal/glial cell markers. 600 
Results of cell counting suggest that cells with markers for neurons (NeuN) and 601 
oligodendrocytes (CNP:ase), but not astrocytes (GFAP) or microglia (Iba-1), are 602 
responsive to IL-6 in the NTS of healthy mice.  603 
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 604 
 605 
 606 
 607 
 608 
 609 
 610 
Figure 611 
1: (A) 612 
PPG 613 
promoter (Glu)-Cre mice were mated with Rosa26 promoter-STOP- 614 
GCaMP3 mice. The Rosa26 promoter is active in most cell types. In cells 615 
with active PPG promoter, the CRE protein cleaved out the STOP sequence 616 
upstream of the GCaMP3 gene. This resulted in expression of the GCaMP3 617 
protein and emission of green fluorescence after stimulation of Ca2+ influx 618 
into the cytosol, e.g after stimulation by IL-6. (B) Immunofluorescence 619 
showing anti-GLP-1 immunoreactivity in red in cells in the NTS of Glu-Cre-620 
GCaMP3 mice. (C) Immunofluorescence showing anti-GFP 621 
immunoreactivity in green in cells in the NTS of Glu-Cre-GCaMP3 mice. (D) 622 
Cells in the NTS of mice with anti-GLP-1 immunoreactivity in red, anti-GFP 623 
immunoreactivity in green, demonstrating co-localization of the two 624 
markers (yellow).  625 
 626 
Figure 2: Interleukin-6 receptor α (IL-6Rα) is co-localized with glucagon like 627 
peptide-1 (GLP-1) in the nucleus of the solitary tract (NTS) of the hindbrain. 628 
Immunohistochemistry showing IL-6Rα-immunoreactivity in red, GLP-1-629 
immunoreactivity in green, and nuclear staining (DAPI) in blue in a coronal 630 
section of the mouse hindbrain. 2A and 2C show overviews of the NTS. 2B and 2D 631 
show magnifications of the areas indicated in 2A and 2C, respectively. One cell 632 
each in in 2B, D, E and F are subject to orthogonal analysis using z-stacks. Orange 633 
arrows indicate examples of co-localization between IL-6Rα and GLP-1. White and 634 
green arrows indicate examples of cells with only IL-6Rα (2E) and only GLP-1 635 
(2F), respectively (2D). Results of cell counting concerning the interrelation 636 
between GLP-1 and IL-6Rα are shown in 2G. Roughly 38% of all GLP-1 positive 637 
cells also stain positively for IL-6Rα and roughly 16% of all IL-6Rα positive cells 638 
stain positively for GLP-1. Images were obtained using the confocal microscope 639 
system described in materials and methods. CC = central canal, NTS = nucleus of 640 
the solitary tract. Scale bars = 100 μm (overview), 10 μm (magnification). 641 
 642 
 643 
Figure 3: Preproglucagon neurons in the NTS respond to IL-6 with a rise in 644 
intracellular Ca2+ 645 
A) Representative image of GCaMP3 fluorescence in PPG neurons in the NTS. Scale 646 
bar = 20µm. B) Traces showing the increase in intracellular Ca2+ in response to 647 
2nM IL-6. Grey = individual cells. Black = average trace. N=6. C) The rise in 648 
intracellular Ca2+ in response to IL-6 is dependent on influx of extracellular Ca2+. 649 
Top panel: Representative trace showing the response to IL-6 (green bars) before, 650 
during, and after exposure to Ca2+-free solution. Note that removal of extracellular 651 
 % % 
100x NeuN/IL-6Rα 58 100x IL-6Rα/NeuN 32 
100x CNP:ase/IL-6Rα 28 100x IL-6Rα/CNP:ase 30 
100x GFAP/IL-6Rα 0-2 100x IL-6Rα/GFAP 0-2 
100x Iba-1/IL-6Rα 0-2 100x IL-6Rα/Iba-1 0-2 
16 
Ca2+ (0Ca2+) also reduces the basal intracellular Ca2+ concentration. Bottom panel: 652 
mean peak change in intracellular Ca2+ in the presence (grey bars, N=19 and 18, 653 
respectively) and absence (white bar, N=28) of extracellular Ca2+. *** indicates 654 
p<0.001 655 
 656 
Figure 4: Interleukin-6 receptor α (IL-6Rα) is localized on neurons and 657 
oligodendrocytes. 658 
Immunohistochemistry showing IL-6Rα-immunoreactivity in green, (NeuN 659 
immunoreactivity in red (4A-B), CNPase immunoreactivity in red (4C-D) and 660 
nuclear staining (DAPI) in blue in a coronal section of the mouse hindbrain. (4A, 661 
C) Overview of the NTS, and (4B, D) magnification of the areas indicated in Fig 3A 662 
and C. Examples of cells with both IL-6Rα and NeuN (4B, orange arrows), cells 663 
with both IL-6Rα and CNPase (4D, orange arrows) as well as a cell only positive 664 
for NeuN (Fig 4B, red arrows) or IL-6Rα (Fig 4D, white arrows) are shown. 665 
Images were obtained using the confocal microscope system described in 666 
materials and methods. CC = central canal. Scale bars = 100 μm (overview), 10 μm 667 
(magnification). 668 
 669 
Figure 5: Interleukin-6 receptor α (IL-6Rα) is not localized on astrocytes or 670 
microglia. 671 
Immunohistochemistry showing IL-6Rα-immunoreactivity in gren and nuclear 672 
staining (DAPI) in blue (5A-D) in a coronal section of the hindbrain. Iba-1-673 
immunoreactivity (5A, B) and GFAP-immunoreactivity (5C, D) are shown in red. 674 
(5A, C) overviews of the mouse NTS, and (5D) a magnification of the area 675 
indicated in 5C. Figure 5B show examples of IL6-Rα-positive and negative 676 
neurons. White arrows indicate cells containing IL6-Rα. There was no co-677 
localization between glial cell markers, GFAP and Iba-1 on one hand, and IL-6Rα 678 
on the other. Images were obtained using the confocal microscope system 679 
described in materials and methods. CC = central canal. Scale bars = 100 μm 680 
(overview), 10 μm (magnification). 681 








